Your search history is turned on.
Date: October 27, 2022 Jurisdictions: Alberta, British Columbia, Saskatchewan
Eastwest - Press Release re. Shares for Debt Settlement (November 4, 2021) (00629598).DOCX EastWest Bioscience Announces Shares for Debt Settlements Vancouver, BC / October 27, 2022 / EastWest Bioscience Inc. (the Company or EastWest) (TSXV: EAST) announces the proposed issuance of 1,436,020 common shares at a price of CDN $0.05 per...
Date: August 11, 2022 Jurisdictions: Alberta, British Columbia, Saskatchewan
EASTWEST Press Release (Early Warning Report - Asriel Augsut 10-22) (00664773).DOC {00664773 v1} NEWS RELEASE Early Warning Report in accordance with National Instrument 62-103 FOR IMMEDIATE RELEASE August 11, 2022 Ms. Ciska Asriel issues this press release pursuant to Part 3 Early Warning Requirements of National Instrum...
EASTWEST Early Warning Report (August 10/22 - Asriel) (00664772).DOC {00664772 v1} EARLY WARNING REPORT Under Part 3 of National Instrument 62-103 1. Name and address of Offeror: Ciska Asriel 260 Okanagan Avenue East Penticton, BC, V2A 3J7 2. Designation and number or principal amount of securities and the Offerors se...
EASTWEST Press Release (Early Warning Report - Asriel Augsut 10/22) (00664773).DOC {00664773 v1} NEWS RELEASE Early Warning Report in accordance with National Instrument 62-103 FOR IMMEDIATE RELEASE August 11, 2022 Ms. Ciska Asriel issues this press release pursuant to Part 3 Early Warning Requirements of National In...
Date: June 29, 2022 Jurisdictions: Alberta, British Columbia, Saskatchewan
EASTWEST BIOSCIENCE INC. Condensed Consolidated Interim Financial Statements For the nine months ended April 30, 2022 (Unaudited Expressed in Canadian dollars) Page | 2 NOTICE OF NO AUDITOR REVIEW OF INTERIM FINANCIAL STATEMENTS Under National Instrum...
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Ciska Asriel, Chief Financial Officer of EastWest Bioscience Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of EastWest Bioscience. (the issuer) for the interim period ended April 3...
Form 52-109FV2 Certification of Interim Filings Venture Issuer Basic Certificate I, Rodney Gelineau, Chief Executive Officer of EastWest Bio Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of EastWest Bioscience. (the issuer) for the interim period ended Apr 30, 2022. ...
EASTWEST BIOSCIENCE INC. MANAGEMENT DISCUSSION AND ANALYSIS For the nine months ended April 30, 2022 Prepared as of June 29, 2022 FORM 51-102F1 The following Management Discussion & Analysis (MD&A) is intended to assist in understanding the trends and significant changes in the financial condition and results of operations of Eas...
Date: April 12, 2021 Jurisdictions: Alberta, British Columbia, Saskatchewan
EastWest - Cylix - Plan of Arrangements News Release - Version 7 Cylix Data And Eastwest Announce Reverse Takeover Transaction Of 1264136 B.C. Ltd. By Cylix Data And Brokered Financing Led By Canaccord Penticton, BC / April 12, 2021 / EastWest Bioscience Inc. (TSX.V: EAST) (EastWest or the Company) and 2747524 Ontario Inc. o/a Cylix Data Group (...
Date: April 8, 2021 Jurisdictions: Alberta, British Columbia, Saskatchewan
Eastwest - Press Release re: Shares for Debt Settlement (April 8, 2021) 3,777,567 (00605981).DOCX EastWest Bioscience Announces Shares for Debt Settlement Vancouver, BC / April 8, 2021 / EastWest Bioscience Inc. (the Company or EastWest) (TSXV: EAST) announces the issuance of 3,777,567 common shares at a price of CDN $0.05 per common sh...